Original Study| Volume 14, ISSUE 4, e299-e305, August 2016

Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center

Published:December 16, 2015DOI:



      We evaluated the incidence and predictors of the use of long-term (2-3 years) versus shorter term androgen deprivation therapy (ADT) in radiation-managed men with high-risk prostate cancer.

      Patients and Methods

      We identified 302 patients from the Dana-Farber Cancer Institute patient registry who had been diagnosed with high-risk prostate cancer (T3a or prostate-specific antigen [PSA] > 20 ng/mL or Gleason score 8-10) from 1993 to 2015. We assessed the intended duration of ADT and used multivariable Cox regression to evaluate the predictors of receiving a shorter course of ADT than recommended by the guidelines (< 2 years).


      The course of ADT intended by physicians increased after the 2008/2009 publication of trials showing the superiority of long-term versus short-term ADT, with 43.5% intending ≥ 2 years before versus 61.4% after (P = .014). Starting in 2010, 49.4% of patients actually received < 2 years of ADT. The most common reasons for receipt of shorter course ADT were intolerance of ADT side effects, patient comorbidity/age, the presence of T3a on magnetic resonance imaging only as the sole high-risk feature, or participation in a clinical trial. Moderate to severe comorbidity assessed using the Adult Comorbidity Evaluation-27 (adjusted hazard ratio [AHR] = 2.94), Gleason score < 8 (AHR = 5.66), and PSA < 20 ng/mL (AHR = 4.19) all predicted for receipt of shorter course ADT (P < .05 for all).


      In a tertiary-care setting, the rates of long-course ADT for high-risk disease have increased since the 2008/2009 trials supporting its use. However, approximately one half of patients continued to receive shorter course ADT, often because of intolerance of side effects, underlying comorbidity, or physician judgment about the aggressiveness of the disease.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer. 2015. Available at: Accessed January 3, 2016.

        • Bolla M.
        • de Reijke T.M.
        • Van Tienhoven G.
        • et al.
        Duration of androgen suppression in the treatment of prostate cancer.
        N Engl J Med. 2009; 360: 2516-2527
        • Horwitz E.M.
        • Bae K.
        • Hanks G.E.
        • et al.
        Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
        J Clin Oncol. 2008; 26: 2497-2504
      2. NCCN Clinical Practice Guidelines in Oncology, Prostate Cancer. 2009. Available at: Accessed January 3, 2016.

        • Nguyen P.L.
        • Alibhai S.M.
        • Basaria S.
        • et al.
        Adverse effects of androgen deprivation therapy and strategies to mitigate them.
        Eur Urol. 2015; 67: 825-836
        • Efstathiou J.A.
        • Bae K.
        • Shipley W.U.
        • et al.
        Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
        Eur Urol. 2008; 54: 816-823
        • Nanda A.
        • Chen M.H.
        • Braccioforte M.H.
        • Moran B.J.
        • D'Amico A.V.
        Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
        JAMA. 2009; 302: 866-873
        • Alibhai S.M.
        • Duong-Hua M.
        • Sutradhar R.
        • et al.
        Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
        J Clin Oncol. 2009; 27: 3452-3458
        • D'Amico A.V.
        • Denham J.W.
        • Crook J.
        • et al.
        Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.
        J Clin Oncol. 2007; 25: 2420-2425
        • Oh W.K.
        • Hayes J.
        • Evan C.
        • et al.
        Development of an integrated prostate cancer research information system.
        Clin Genitourin Cancer. 2006; 5: 61-66
        • Kallogjeri D.
        • Piccirillo J.F.
        • Spitznagel Jr., E.L.
        • Steyerberg E.W.
        Comparison of scoring methods for ACE-27: simpler is better.
        J Geriatr Oncol. 2012; 3: 238-245
        • Nabid A.
        • Carrier N.
        • Martin A.-G.
        • et al.
        Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized trial.
        J Clin Oncol. 2013; 31 (abstract LBA4510)
        • Joniau S.
        • Briganti A.
        • Gontero P.
        • et al.
        Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study.
        Eur Urol. 2015; 67: 157-164
        • Spahn M.
        • Joniau S.
        • Gontero P.
        • et al.
        Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients.
        Eur Urol. 2010; 58: 1-11
        • Walz J.
        • Joniau S.
        • Chun F.K.
        • et al.
        Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.
        BJU Int. 2011; 107: 765-770
        • Lee M.
        • Jim H.S.
        • Fishman M.
        • et al.
        Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
        Psychooncology. 2015; 24: 472-477
        • Ziehr D.R.
        • Chen M.H.
        • Zhang D.
        • et al.
        Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
        BJU Int. 2015; 116: 358-365
        • D'Amico A.V.
        • Chen M.H.
        • Renshaw A.A.
        • Loffredo M.
        • Kantoff P.W.
        Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.
        JAMA. 2008; 299: 289-295
        • Nguyen P.L.
        • Je Y.
        • Schutz F.A.
        • et al.
        Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
        JAMA. 2011; 306: 2359-2366
        • Muralidhar V.
        • Dinh K.T.
        • Mahal B.A.
        • et al.
        Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: implications for managing patients upstaged on prostate magnetic resonance imaging.
        Urol Oncol. 2015; 33: e19-e25
        • Gonzalez B.D.
        • Jim H.S.
        • Booth-Jones M.
        • et al.
        Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison.
        J Clin Oncol. 2015; 33: 2021-2027
        • DiBlasio C.J.
        • Malcolm J.B.
        • Derweesh I.H.
        • et al.
        Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
        BJU Int. 2008; 102: 39-43